Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Meneldor is a venture capital organization based in the Netherlands, established to invest in early-stage biotech and pharmaceutical companies. Founded by a team of specialists, Meneldor provides investors the opportunity to engage in this complex sector alongside experts. The firm conducts thorough assessments of potential portfolio companies, evaluating factors such as scientific soundness, intellectual property, medical needs, market potential, competition, management, financial requirements, and valuation before making investment decisions.
Currently, Meneldor manages a portfolio of five companies, focusing on projects that are in the preclinical, Phase I, or Phase II stages. The firm emphasizes strong intellectual property and clear clinical endpoints in its investment strategy. Meneldor operates primarily in Western Europe, where it seeks to address significant unmet medical needs through its investments.
Meneldor's notable milestones include establishing a reputation for rigorous due diligence and a commitment to supporting innovative healthcare solutions. The firm is located in the Netherlands and has built a strong base of limited partners who share its vision for advancing healthcare through biotechnology.
Meneldor primarily invests in early-stage biotech and pharmaceutical companies that are developing new biological or chemical molecular entities. The organization targets projects that are in preclinical, Phase I, or Phase II stages, particularly those with clear clinical endpoints. Meneldor's geographic focus is on Western Europe, where it seeks companies that address significant unmet medical needs and possess strong intellectual property.
The firm looks for startups that demonstrate a solid understanding of their market and competition, as well as a capable management team. Meneldor's investment strategy emphasizes the importance of scientific validation and the potential for substantial market impact. The organization is particularly interested in companies that are innovating in areas such as drug development and therapeutic solutions.
Meneldor's current portfolio includes five notable companies:
These companies exemplify Meneldor's commitment to investing in innovative solutions that address critical healthcare challenges.
Paul Lelieveld, Ir., MSc. - Founding Partner. Paul has extensive experience in the biotech sector and has led numerous investments in early-stage companies.
Frans van Dalen, Pharm. D. - Founding Partner. Frans brings a strong pharmaceutical background and expertise in drug development and commercialization.
Mark Buscher - Intellectual Property Expert. Mark specializes in intellectual property strategy and has a track record of supporting biotech companies in protecting their innovations.
Peter Goedings, Dr. - Senior Clinical Expert. Peter has significant experience in clinical research and development, providing valuable insights to portfolio companies.
Cees Stouten, MSc. - Senior Drug Development & Manufacturing Expert. Cees focuses on the operational aspects of drug development, ensuring that portfolio companies are well-positioned for success.
To pitch Meneldor, founders should send an email to info@meneldor.nl. It is important to include a comprehensive deck that outlines the business model, scientific basis, and market opportunity. Meneldor appreciates detailed information about the team and their qualifications.
Response times may vary, but founders can generally expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review process.
What are Meneldor's investment criteria?
Meneldor invests in early-stage biotech and pharmaceutical companies that are developing new biological or chemical molecular entities. The firm focuses on projects in preclinical, Phase I, or Phase II stages, particularly those with clear clinical endpoints and strong intellectual property.
How can I apply or pitch to Meneldor?
Founders can pitch to Meneldor by sending an email to info@meneldor.nl. It is advisable to include a detailed business plan and information about the scientific basis of the project.
What makes Meneldor different from other investors?
Meneldor differentiates itself by focusing exclusively on early-stage biotech and pharmaceutical companies, leveraging the expertise of its founding partners and team members who have extensive backgrounds in the sector.
What is Meneldor's geographic scope?
The firm primarily invests in companies located in Western Europe, allowing it to closely monitor and support its portfolio companies.
What is Meneldor's approach to post-investment involvement?
Meneldor actively engages with its portfolio companies, providing guidance and support in areas such as scientific validation, market strategy, and operational management.
What is the typical check size for investments?
Meneldor invests at the pre-seed, seed, and seed-plus stages, with check sizes varying based on the specific needs of the portfolio company and the stage of development.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.